Skip to main content

CORRECTION article

Front. Pharmacol., 05 September 2023
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1281416

Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib

This article is a correction to:

  1. Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib

    1. Read original article
Mohamed E. Shaker Mohamed E. Shaker1*Hesham A. M. GomaaHesham A. M. Gomaa1Sara H. HazemSara H. Hazem2Mohamed A. AbdelgawadMohamed A. Abdelgawad3Mohamed El-Mesery,Mohamed El-Mesery4,5Ahmed A. Shaaban,Ahmed A. Shaaban2,6
  • 1Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Saudi Arabia
  • 2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
  • 3Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al-Jawf, Saudi Arabia
  • 4Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
  • 5Division of Biochemical Pharmacology, Department of Biology, University of Konstanz, Konstanz, Germany
  • 6Department of Pharmacology and Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt

A Corrigendum on
Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib

by Shaker ME, Gomaa HAM, Hazem SH, Abdelgawad MA, El-Mesery M and Shaaban AA (2023). Front. Pharmacol. 14:1212771. doi: 10.3389/fphar.2023.1212771

In the published article, there was an error in Affiliation for first author “Mohamed E. Shaker.” Instead of affiliations 1 and 2, the author should only have affiliation 1.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: alpelisib, phosphatidylinositol 3-kinase, acetaminophen, hepatotoxicity, DAMPs

Citation: Shaker ME, Gomaa HAM, Hazem SH, Abdelgawad MA, El-Mesery M and Shaaban AA (2023) Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib. Front. Pharmacol. 14:1281416. doi: 10.3389/fphar.2023.1281416

Received: 22 August 2023; Accepted: 30 August 2023;
Published: 05 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Shaker, Gomaa, Hazem, Abdelgawad, El-Mesery and Shaaban. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Mohamed E. Shaker, bWVsc2F5ZWRAanUuZWR1LnNh, bXNoYWtlcjIyMjJAeWFob28uY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.